Mastocytosis with skin manifestations: Current status

Journal of the European Academy of Dermatology and Venereology

Volumn 13, Issue 3, 1999, Pages 155-165

  Katsambas, Andreas D ^a   Karpouzis, Anthony J ^a   Koumantaki Mathioudaki, Elma ^a   Jorizzo, Joseph L ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Mast cell; Mastocytosis

Indexed keywords

ALPHA INTERFERON; CALCIUM; CETIRIZINE; CHLORAMBUCIL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; FLUORIDE SODIUM; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; KETOTIFEN; LORATADINE; MEQUITAZINE; MIZOLASTINE; NIFEDIPINE; PSORALEN; VITAMIN D;

CELL MIGRATION; CELLULAR IMMUNITY; DRUG MECHANISM; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; INFLAMMATION; MAST CELL; MASTOCYTOSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; PUVA; RASH; RECURRENT DISEASE; REVIEW; SKIN BIOPSY; SKIN DEFECT; SPLENECTOMY; TELANGIECTASIA; URTICARIA PIGMENTOSA;

BONE AND BONES; CELL DEGRANULATION; CELL DIVISION; CELL MOVEMENT; CHRONIC DISEASE; CONNECTIVE TISSUE; HUMANS; IMMUNITY, CELLULAR; MAST CELLS; MASTOCYTOSIS; PROGNOSIS; RECURRENCE;

EID: 0032738871     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0926-9959(99)00093-8     Document Type: Review

References (92)

1. Metcalfe DD. Classification and diagnosis of mastocytosis: current status (Suppl.). J Invest Dermatol 1991;96:25-45.
2. Galli SJ. New concepts about the mast cell. New Engl J Med 1993;328:257-265.
3. Longley J, Duffy TP, Kohn S. The mast cell and mast cell disease. J Am Acad Dermatol 1995;32(4):545-561.
4. Lazarus GS. Mastocytosis: new understandings in cutaneous pathophysiology. J Dermatol 1996;23:769-7772.
5. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 1991; 146: 1410-1415.
6. Kirshenbaum AS, Goff JP, Kessler SW, Mican JM, Zsebo KM, Metcalfe DD. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 1992;148:772-777.
7. Langley KE, Bennett LG, Wypych J, et al. Soluble stem cell factor in human serum. Blood 1993;81:656-660.
8. Anderson DM, Lyman SD, Baird A, et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 1990;63:235-243.
9. Toyota N, Hashimoto Y, Matsuo S, lizuka H. Transforming growth factor b1 inhibits IL-3- and IL-4- dependent mouse connective tissue-type mast cell proliferation. Arch Dermatol Res 1995;287:198-201.
10. Longley BJ, Tyrell L, Lu S, Ma Y, Klump V, Murphy GF. Chronically KIT-stimulated clonally-derived human mast cells show heterogeneity in different tissue microenvironment. J Invest Dermatol 1997;108:792-796.
11. Weber S, Krüger-Krasagakes S, Grabbe J, Zuberbier T, Czarnetzki BM. Mast Cells. Int J Dermatol 1995;34(1):1-10.
12. Adrien, A., Lacour, J.P., Ortonne, J.P. Les Mastocytoses. Encyc Méd Chir (Paris, France), Dermatologie 12795A10 1986;7:14.
13. Aquilina C. Le mastocyte en dermatologie. Dermatologie Pratique 1991;81:15-20.
14. Helwig EB, Graham JH. Anogenital (extramammary) Paget's disease. Cancer 1963;16:387-403.
15. Johnson WC, Helwig EB. Histochemistry of the acid mucopolysaccharides of the skin in normal and certain pathological conditions. Am J Clin Pathol 1963;40:123-131.
16. Logan ME, Zaim MT. Histologic stains in dermatopathology. J Am Acad Dermatol 1990;22:820-830.
17. Galli SJ. New insights into 'the riddle of the mast cells': microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 1990;62:5-33.
18. Paus R, Heinzelmann T, Robiczek S, Czarnetzki BM, Maurer M. Substance P stimulates mirune epidermal Keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res 1995;287:500-502.
19. Weber S, Ruh B, Krüger-Krasagakes S, Czarnetzki BM. Adhesion molecules on the human mast cell line HMC-1 are upregulated during cell activation. Arch Dermatol Res 1995;287:695-698.
20. Hamann K, Haas N, Grabbe J, Welker P, Czarnetzki BM. Two novel mast cell phenotypic markers, monoclonal antibodies Ki-MC1 and Ki-M1P, identify distinct mast cell subtypes. Br J Dermatol 1995;133:547-552.
21. Columbo M, Horowitz EM, Botana LM, et al. The human recombinant c-Kit receptor ligand rhSCF, induces mediator release from human cutaneous mast cells, and enhances IgE-dependent mediator release from both skin mast cells and peripheral vlood basophls. J Immunol 1992;149:599-608.
22. Katz AM, Rosenthal D, Sauder DN. Cell adhesion molecules, structure, function and implication in a variety of cutaneous and other pathologic conditions. Int J Dermatol 1991;30:153-160.
23. Griffiths CEM. La circulation des cellules dans la peau. Ann Dermatol Vénéréol 1992;119:51-55.
24. Karpouzis AJ. Review and reexamination of the histological and photobiological features of polymorphous light eruption in comparison with Lupus Erythematosus. Thesis for Doctorate. National Athens University Medical School, Greece. 1993;221 pages.
25. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-434.
26. Schechter NM, Irani AA, Sprows JL, Abernethy J, Wintroub B, Schwartz LB. Identification of a cathepisin G-like proteinase in the MCTC type of human mast cell. J Immunol 1990;145:2652-2661.
27. Ruh B, Weber S, Czarnetzki BM. ;Down regulation by PMA and calcium ionophor of mast cell surface expression of leukosialin (CD43). Arch Dermatol Res 1994;286:166.
28. Craig SS, Schechter NM, Schwartz LB. Ultrastructrural analysis of human Tand TC mast cells identified by immunoelectron microscopy. Lab Invest 1988;58:682-691.
29. Weidner N, Austen KF. Ultrastructural and immunohistochemical characterization of normal mast cells at multiple body sites . J Invest Derm (Suppl.) 1991;96:265-315.
30. Tharp MD. Mast cell disease and its diagnosis. J Invest Dermatol 1995;104(6):885-886.
31. Rothe MJ, Nowak M, Kerdel FA. The mast cell in health and disease. J Am Acad Dermatol 1990;23:615-624.
32. Unväs B. Chemistry and storage function of mast cell granules. J Invest Dermatol 1978;71:76-80.
33. Schechter NM, Wang ZM, Blacher RW, Lessin SR, Lazarus GS, Rubin H. Determination of the primary structures of mentosa human skin chymase and cathepsin G from cutaneous mast cells of urticaria pignemtose lesions. J Immunol 1994;152:4062-4069.
34. Greaves MW, Sabroe RA. Histamine: The Quintessential Mediator. J Dermatol 1996;23:735-740.
35. Sayama S, lozzo RV, Lazarus GC, Schechter NM. Human skin chymotrypsin-like proteinase chymase: subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans. J Biol Chem 1987;262:808-815.
36. Gordon JR, Galli SJ. Mast cells as a source of both preformed and imuunologically inducible TNF-α/cachectin. Nature 1990;346:274-276.
37. Möller A, Grabbe J, Czarnetzki BM. Mast cells and their mediators in immediate and delayed immune reactions. Skin Pharmacol 1991;4(Suppl. 1):56-63.
38. Morrow JD, Guzzo C, Lazarus G, Oates JA, Roberts LJ. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of PGD2. J Invest Dermatol 1995;104(6):937-940.
39. Metcalfe DD. Introduction. J Invest Dermatol 1991;96(Suppl.):15.
40. Baadsgaard O, Wang T. Immune refulation in allergic and irritant skin reactions. Int J Dermatol 1991;30:161-172.
41. Galli S, Dvorak AM. What do mast cells have to do with delayed hypersensitivity? Lab Invest 1984;50:365-368.
42. Yaniv R. Clinical advances in mastocytosis. J Invest Dermatol 1992;98(5):817.
43. Roberts LJ, Sweetman BJ, Lewis RA, Austen KF, Oates JA. Increased production of prostaglandin D2 in patients with systemic mastocytosis. New Engl J Med 1980;303:1400-1404.
44. Werfel T, Oppermann M, Begemann G, Götze O, Zwirner J. C5α receptors are detectable on mast cells in normal human skin and in psoriatic plaques but not in weal and flare reactions or in urticaria pignentosa by immunohistochemistry. Arch Dermatol Res 1997;289:83-86.
45. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia; a review. Histopathology 1979;3:349-365.
46. Horny HP, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985;16:808-814.
47. Horny HP, Parwaresch MR, Kaiserling E, et al. Mast cell sarcoma of the larynx. J Clin Pathol 1986;39:596-602.
48. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease: analysis of 58 cases and literature review. Medicine 1988;67:345-368.
49. Le Bozec P. Les mastocytoses systémiques. Ann Dermatol Vénéréol 1992;119:103-113.
50. Fine JD. Mastocytosis. Int J Dermatol 1980;19:117-123.
51. Olafsson JH. Cutaneous and systemic mastocytosis in adults. A clinical, histopathological and immunological evaluation in relation to histamine metabolism. Acta Derm-venereol 1985;115:1-43.
52. Riddel B, Olafsson JH, Roupe G, et al. The bone narrow in urticaria pigmentosa and systemic mastocytosis. Arch Dermatol 1986;122:422-427.
53. Czarnetzki BM, Kolde G, Schoemann A, Urbanitz S, Urbanitz D. Bone narrow findings in adult patients with urticaria pigmentosa. J Am Acad Dermatol 1988;18:45-51.
54. Guzzo C, Lavker R, Roberts LJ, Fox R, Schechter N, Lazarus G. Urticaria pigmentosa: systemic evaluation and successful treatment with topical steroids. Arch Dermatol 1991;127:191-196.
55. Soter NA. The skin in mastocytosis. J Invest Dermatol 1991;3:325-395.
56. Czarnetzki BM, Behrendt H. Urticaria pigmentosa: clinical picture and responses to oral sodium cromoglycate. Br J Dermatol 1981;105:563-567.
57. Civatte J. Histopathologie Cutanée. Flammarion Médecine-Sciences, Paris, 1982.
58. Stern RL, Manders SM, Buttress SH, Heymann WR. Urticaria pigmentosa with massive eosinophila. Pediatr Dermatol 1997;14(4):284-286.
59. Webb TA, Li CH, Yam LT. Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Cancer 1982;49(5):927-938.
60. De Villez RL, Limmer BL. Juvenile xanthogranuloma and urticaria pignentosa. Arch Dermatol 1975;111:365-366.
61. Benzerara N, Combemale P, Abitan R, Kanitakis J, Guennoc B, Chouvet B. Xanthogranulome de l'adulte et mastocytose cutanée. Ann Dermatol Vénéréol 1994;121:489-492.
62. Anstey A, Lowe DG, Kirby JD, Horton MA. Familiar mastocytosis: a clinical, immunophenotypic, light and electron microscopic study. Br J Dermatol 1991;125:583-587.
63. Pec J, Palencarova E, Malisova S, et al. Urticaria pigmentosa in identical male twins. Acta Derm Venereol (Stockh.) 1995;75:244-252.
64. Claudy AL. Adult-onset urticaria pigmentosa and eruptive syringomas. J Am Acad Dermatol 1988;19:135.
65. Mertz H, Veien NK. Eruptive syringoma micking urticaria pigmentosa. Acta Derm Venereol (Stockh.) 1993;73:136-137.
66. Enginger V, Bedane C, Pistorius MA, Lavignac C, Leboutet MJ, Bonnetblanc JM. Mastocytose inguinale avec infiltrat histiocytaire. Ann Dermatol Vénéréol 1995;122:536-539.
67. Koeppel MC, Sayag J. Mastocytose Lineaire. À type de Telangectasia macularis eruptiva perstans. Ann Dermatol Vénéréol 1990;117:109-111.
68. Gonzalez-Castro U, Luelmo-Aguilar J, Castells -Rodellas A. Unilateral facical telangiectasia macularis eruptiva perstans. Int J Dermatol 1993;32(2):123-124.
69. Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. J Invest Dermatol (Suppl.) 1991;96:155-185.
70. Labeille B. Maastocytose cutanée diffuse congenitale. Medical staff. Dermatol Lab Roche-Posay 1991;10:6-9.
71. Legrain V, Taï'eb A, Bioulac-Sage P, Maleville J. Mastocytose cutanée diffuse sans lésions permanente. Ann Dermatol Vénéréol 1994;121:561-564.
72. Requena L. Erythrodermic mastocytosis. Cutis 1992;49 (3):189-192.
73. Rasmussen JE. Xanthelasmoidea. An unusual case of Urticaria pigmentosa. Arch Dermatol 1976;112:1270-1271.
74. Leaf FA, Jaecks EP, Rodriguez DR. Bullous urticatria pigmentosa. Cutis 1996;58:358-360.
75. Wymenga ANM, De Monchy JGR, De Vries EGE. The carcinoid syndrome and angioedema. Ann Intern Med 1995;123(8):636.
76. Roberts LJ, Oates JA. Biochemical diagnosis of systemic mast cell disorders. J Invest Dermatol (Suppl.) 1991;96:195-255.
77. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Womens Hospital. J Invest Dermatol (Suppl.) 1991;96:55-145.
78. Austen KF. Systemic mastocytosis. New Engl J Med 1992;326(9):639-640.
79. Metcalfe DD. The liver, spleen, and lymph nodes in mastocytosis. J Invest Dermatol (Suppl.) 1991;96:455-465.
80. Miner PB. The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis. J Invest Dermatol (Suppl.) 1991;96:405-445.
81. Parker RI. Hematological aspects of mastocytosis: I. Bone marrow pathology in adult and pediatric systemic mast cell disease. J Invest Dermatol (Suppl.) 1991;96:475-515.
82. Azana JM, Torrelo A, Mediero IG, Zambrano A. Urticaria pigmentosa: a review of 67 pediatric cases. Pediatr Dermatol 1994;11(2):102-106.
83. Venencie PY. Mastocytoses. In: Dubertret L, editor. Thérapeutique dermatologique. Paris: Flammarion-Médecine-Sciences, 1991:363-365.
84. Stein DH. Mastocytosis: a review. Pediatr Dermatol 1986;3:365-375.
85. Metcalfe DD. The treatment of mastocytosis: an overview. J Invest Dermatol (Suppl.) 1991;96:555-595.
86. Karpouzis AJ. Contribution à la conduite thérapeutique devant les Urticaires, par l'étude sur l'action d'un nouvel antihistaminique, la cétirizine. Faculté de Médecine Lariboisière - St. Louis, Université Paris VII. 1989-1990:112.
87. Michaud V. Les mastocytoses. Dermatologie Pratique 1988;24:1-3.
88. Stege H, Schöpf E, Ruzicka T, Krutmann J. High-dose UVA1 for Urticaria pigmentosa. Lancet 1996;January 6:64:347.
89. Higgins EM, Humphreys S, Du Vivier AWP. Urticaria pigmentosa-response to topical steroids. Clin Exp Dermatol 1994;19:438-440.
90. Delaporte E, Piérard E, Wolthers BG. Interferon-a in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol 1995;132:479-482.
91. Kolde G. Long-term effect of Interferon alpha treatment in mastocytosis. Br J Dermatol 1996;134:1164-1165.
92. Ogg GS, Rosbotham JL, Mac Donald DM. Urticaria pigmentosa coexisting with multiple myeloma. Clin Exp Dermatol 1996;21:365-366.